Schizophrenia - advances in drug therapy

Bibliography

• FARDE L, NORDSTROM AL, WIESEL FA et al: Positron emission tomographic analysis of central Di and D2dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiat (1992) 49:538-544. A very valuable paper describing the application of PET imaging to determining in vivo receptor occupancy by antipsychotic drugs; thresholds for antipsychotic and EPS effects are differentiated, and clozapine is shown to be clearly different.
   Google Scholar
• WHITE FJ, WANG RY: Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science (1983) 221:1054-1057. This paper had a major impact on modelling and understanding atypical antipsychotic action.
   Google Scholar
• REYNOLDS GP: Neurotransmitter systems in schizophrenia. Int. Rev. Neurobiol. (1995) 38:305-339. A comprehensive review of the evidence for the involvement of various transmitter systems in schizophrenia.
   Google Scholar
• KANE JM, HONIGFELD G, SINGER J et al: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psy-chiat (1988) 35:789-796. This paper describes the clinical observations that led to the re-in-troduction of clozapine.
   Google Scholar
• BAKSHI V, GEYER MA: Antagonism of PCP-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (1995) 122:198-201. A useful model for antipsychotic drug development with construct validity, independent of dopaminergic systems.
   Google Scholar
• ROBERTSON GS, MATSUMURA H, FIBIGER H: Induction patterns of fag-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Phar-macol. Exp. Ther. (1994) 271:1058-1066. Another valuable test hat may identify antipychotic potential against negative symptoms or treatment resistance.
   Google Scholar
• SCHOTTE A, JANSSEN PFM, GOMMEREN W eta].: Risperi- done compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychophar-macology (1996) 124:57-73. A comprehensive investigation of the receptor pharmacology of several antipsychotic drugs.
   Google Scholar
• REYNOLDS GP: What is an atypical antipsychotic? J.
   Google Scholar
• •Psychopharmacol. (1997) 11 (In Press.) A review of the receptor mechanisms that may underlie 'atypicality'.
   Google Scholar
• KLIMA MT, GOLDSTEIN JM, TRAINOR DA et al: Putative atypical antipsychotics with mixed dopaminergic DO and serotonergic (5-11T2) activity: the design evolu-tion of ZD 363& Bioorg. Med. Chem. Lett. (1995) 5:1795–1800.
   Web of Science ®Google Scholar
• OHNO Y, ISHIBASHI T, OKADA K, ISHIDA K, NAKAMURAM: Effects of subchronic treatments with SM-9018, a novel 5-11T2 and D2 antagonist, on dopamine and 5-HT receptors in rats. Prog. Neuropsychopharmacol Biol. Psy-chial (1995) 19:1091–1101.
   PubMed Web of Science ®Google Scholar
• JONES-HUMBLE SA, DURCAN MJ, LYERLY D et al: Preclini-cal neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic. NeuropFchopharma-cology (1996) 15:217–230.
   PubMed Web of Science ®Google Scholar
• BJORK A, CHRISTENSSON E, ALBINSSON A et al: In thesearch for a novel class of antipsychotic drugs: preclini-cal pharmacology of FG5803, a 1-pipiperazinecarbox-amide derivative. J. Pharmacol. Exp. Ther. (1994) 271:1338–1347.
   PubMed Web of Science ®Google Scholar
• OKA M, NODA Y, OCHI Y eta].: Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S 2 antagonist properties. J. Pharmacol. Exp. Ther. (1993) 264:158–165.
   Google Scholar
• REYNOLDS GP, CZUDEK C: New approaches to the drug treatment of schizophrenia. Adv. Pharmacol. (1995)32:461-503. A fairly comprehensive and critical review of the main receptor mechanisms of known and potential antipsychotic action.
   Google Scholar
• BUSATTO GF, KERWIN RW: Perspectives on the role of serotonergic mechanisms in the pharmacology ofschizophrenia. J. Psychopharmacol (1997) 11:3-12. A valuable review of the role of 5-HT systems in the pathology, genetics and treatment of schizophrenia; this is followed in the journal by six useful 'critiques' commenting and elaborating on the review.
   Google Scholar
• SONI SD, MALIK A, SCHIFF AA: Sulpiride in negative schizophrenia: a placebo-controlled double-blind asHum. Psychopharmacol (1990) 5:233–238.
   Google Scholar
• TECOTT LH, SUN LM, AKANA SF eta].: Eating disorder andepilepsy in mice lacking 5-11T2c serotonin receptors.Nature (1995) 374:542-546. Potentially an important observation that may underlie the weight gain induced by some antipsychotic drugs.
   Google Scholar
• ROTH BL, CRAIGO SC, CHOUDHARY MS etal: Binding of typical and atypical antipsychotic agents to 5-hy- droxytryptamine-6 and 5-hydroxytryptamine-7 recep- tors. J. Pharmacol. Exp. Ther. (1994) 263:1403-1410. A report of the high affinity of many antipsychotic drugs for these newly-identified receptors.
   Google Scholar
• MASON SL, REYNOLDS GP: Clozapine has sub-micromo-lar affinity for 5-HT1A receptors in human brain tissue. Eur. j Pharmacol. (1992) 221:397–398.
   PubMed Web of Science ®Google Scholar
• BOWEN DM, FRANCIS PT, PANGALOS MN, STEPHENS PH, PROCTOR AW: Treatment strategies for Alzheimer's disease. Lancet (1992) 339:132. This letter noted the effects of 5-HT1A drugs on cortical glutamatergic neurones and indicated a possible clinical application.
   Google Scholar
• LITMAN RE, HONG WW, VVEISSMAN EM et al: Idazoxan, an a2-antagonist, augments fluphenazine in schizo-phrenic patients: a pilot study. J. Clin. Pharmacol. (1993) 13:264–267.
   Google Scholar
• LITMAN RE, SU TP, POTTER WZ, HONG WW, PICKAR D:
   Google Scholar
• •Idazoxan and response to typical neuroleptics in treat-ment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br. J. Psychiat (1996) 168:571-579. These two papers highlight the potential importance of a2-receptor antagonism in clozapine's unique effects on treatment-refractory patients.
   Google Scholar
• BLAKE TJ, REYNOLDS GP: Antipsychotic drug action at a2-adrenoceptor subtypes in post-mortem human brain. J. Psychopharmacol. (1996) 10:A7.
   Google Scholar
• MOORE NA, CALLIGARO DO, WONG DT, BYMASTER F, TYE NC: The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs (1993) 2:281–293.
   Google Scholar
• DELINI-STULA A, BERDAH-TORDJMAN D: Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia - a study group report J. Psychial Res. (1996) 30:239–250.
   Google Scholar
• JAVITT DC, ZYLBERMAN I, ZUKIN SR, HERESCO-LEVY U, LINDENMAYER JP: Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiat (1994) 151:1234-1236. One of several studies suggesting that glycine might be a valuable antipsychotic treatment/supplement.
   Google Scholar
• BRISTOW LJ, FLATMAN KL, HUTSON PH eta].: The atypical neuroleptic profile of the glycine/N-methyl-D-as par tat e receptor antagonist, L-701324, in rodents. J. Pharmacol Exp. Ther. (1996) 277:578–585.
   Google Scholar
• LARGENT BL, WIKSTROM H, SNOWMAN AM, SNYDER SH: Novel antipsychotic drugs share high affinity for sigma receptors. Eur. j Pharmacol. (1988) 155:345–347.
   PubMed Web of Science ®Google Scholar
• LANG A, SOOSAAR A, KOKS S et al: Pharmacological comparison of antipsychotic drugs and sigma-antago-nists in rodents. Pharmacol. Toxicol (1994) 75:222–227.
   PubMedGoogle Scholar
• MAJ J, ROGOZ Z, SKUZA G, MAZELA H: Neuropharrna-cological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity. Eur. J. Pharmacol (1996) 315:235–243.
   PubMed Web of Science ®Google Scholar
• OGAWA S, OKUYAMA S, TSUCHIDA K, ARAKI H, OTOMO S: The sigma selective ligand NE-100 attenuates the effect of phencyclidine in a rat diving model. Gen. Pharmacol. (1995) 26:177–182.
   PubMedGoogle Scholar
• RASMUSSEN K: Therapeutic potential of cholecystok- inin-B antagonists. Exp. Opin. Invest Drugs (1995) 4:313-322. A useful review.
   Google Scholar
• HOWARD HR: Antipsychotic drugs: recent developments and novel agents. Exp. Opin. Ther. Patents (1997) (In Press.) An up-to-date assessment of recent patents for potential antipsy-chotics.
   Google Scholar
• REYNOLDS GP: The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs (1996) 51:7-11. A highly critical review of the (lack of) evidence for the importance of the dopamine D4 receptor in the pathology of schizophrenia and as a drug target.
   Google Scholar
• KRAMER M, ZIMBROFF D, LAST B eta].: The effects of a selective D4 antagonist (L-745,870) in acutely psychotic schizophrenic patients. Poster presentation 36th NCDEU. Boca Raton, Florida (1996). The first report of the clinical effects of a D4 antagonist in schizo-phrenia: an unequivocal negative result was obtained.
   Google Scholar
• HEUILLET E, PETITET F, MIGNANI S eta].: The naphtho-sulfam derivative RP 62203 (fananserin) has a high affinity for the dopamine D4 receptor. Eur. j Pharmacol (1996) 314:229–233.
   Google Scholar
• MELTZER LT, CHRISTOFFERSEN CL, CORBIN AE et al.: CI-1007, a dopamine partial agonist and potential an- tipsychotic agent. II. Neurophysiological and behav-ioral effects. J. Pharmacol. Exp. Ther. (1995) 274:912–920.
   PubMed Web of Science ®Google Scholar
• KIKUCHI T, TOTTORI K, UWAHODO Y et al.: 7-(444-(2,3-dichloropheny0-1-p ip e raz inyl Ibutyloxy)-3,4-dihydro-2-(11-) -quinolone (0PC-14597), a new putative antipsy-chotic drug with both presynaptic dopamine autore-ceptor agonist activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. (1995) 274:329–336.
   PubMed Web of Science ®Google Scholar
• NEEDHAM P, SKILL MJ, HEAL DJ: Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Eur. Neuropsychopharmacol. (1995) 5:331–332.
   Google Scholar